As discussed above, multiple studies using pre-clinical cancer cellular models have shown that genetic silencing of LEDGF/p75 sensitizes cells to various classes of chemotherapeutic drugs including DNA damaging agents, PARP inhibitors, antimetabolites, and microtubule-stabilizing taxanes [36,40,41,46,47,48,49,83,135]. This evidence concerns the gene PSIP1 and cancer.